201 related articles for article (PubMed ID: 17366003)
1. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects.
Nieminen T; Lehtimäki T; Mäenpää J; Ropo A; Uusitalo H; Kähönen M
Scand J Clin Lab Invest; 2007; 67(2):237-45. PubMed ID: 17366003
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.
Nieminen T; Uusitalo H; Mäenpää J; Turjanmaa V; Rane A; Lundgren S; Ropo A; Rontu R; Lehtimäki T; Kähönen M
Eur J Clin Pharmacol; 2005 Dec; 61(11):811-9. PubMed ID: 16315032
[TBL] [Abstract][Full Text] [Related]
4. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.
Korte JM; Kaila T; Saari KM
Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):430-5. PubMed ID: 12107508
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG).
Ohno Y; Iga T; Yamada Y; Nagahara M; Araie M; Takayanagi R
Curr Eye Res; 2005 Apr; 30(4):319-28. PubMed ID: 16020262
[TBL] [Abstract][Full Text] [Related]
6. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients.
Nieminen T; Uusitalo H; Turjanmaa V; Bjärnhall G; Hedenström H; Mäenpää J; Ropo A; Heikkilä P; Kähönen M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):369-74. PubMed ID: 15912390
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of ophthalmic timolol: new aspects of an old drug.
Volotinen M; Hakkola J; Pelkonen O; Vapaatalo H; Mäenpää J
Basic Clin Pharmacol Toxicol; 2011 May; 108(5):297-303. PubMed ID: 21385322
[TBL] [Abstract][Full Text] [Related]
8. Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor.
Volotinen M; Mäenpää J; Kautiainen H; Tolonen A; Uusitalo J; Ropo A; Vapaatalo H; Aine E
Eur J Pharm Sci; 2009 Feb; 36(2-3):292-6. PubMed ID: 19013521
[TBL] [Abstract][Full Text] [Related]
9. Cardiac safety of ophthalmic timolol.
Mäenpää J; Pelkonen O
Expert Opin Drug Saf; 2016 Nov; 15(11):1549-1561. PubMed ID: 27534869
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels and systemic safety of 0.1% unpreserved timolol maleate gel, 0.5% timolol aqueous solution and 0.5% timolol maleate gel.
Bonnin N; Nezzar H; Dubray C; Renault D; Olmiere C; Chiambaretta F
J Fr Ophtalmol; 2012 Jan; 35(1):9-16. PubMed ID: 21992993
[TBL] [Abstract][Full Text] [Related]
11. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers.
Ishii Y; Nakamura K; Tsutsumi K; Kotegawa T; Nakano S; Nakatsuka K
J Clin Pharmacol; 2000 Feb; 40(2):193-9. PubMed ID: 10664926
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
13. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
Schenker H; Maloney S; Liss C; Gormley G; Hartenbaum D
Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431
[TBL] [Abstract][Full Text] [Related]
14. [The influence of 0.85% RS-timolol and 0.5% S-timolol on intraocular pressure and systemic arterial blood pressure, heart rate, ECG, expiratory capacity in patients with ocular hypertension and primary open-angle glaucoma].
Czechowicz-Janicka K; Staszkiewicz J; Strzałkowska M; Krajewska M; Popiołek B; Christman A
Klin Oczna; 1999; 101(5):333-7. PubMed ID: 10714069
[TBL] [Abstract][Full Text] [Related]
15. Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses.
Phan TM; Nguyen KP; Giacomini JC; Lee DA
J Ocul Pharmacol; 1991; 7(3):243-52. PubMed ID: 1686051
[TBL] [Abstract][Full Text] [Related]
16. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops.
Mäenpää J; Volotinen-Maja M; Kautiainen H; Neuvonen M; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2014 Dec; 42(12):2068-76. PubMed ID: 25261563
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
Niño J; Tahvanainen K; Uusitalo H; Turjanmaa V; Hutri-Kähönen N; Kaila T; Ropo A; Kuusela T; Kähönen M
Clin Physiol Funct Imaging; 2002 Jul; 22(4):271-8. PubMed ID: 12402450
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic and systemic side effects of ocular beta-adrenergic antagonists in anesthetized dogs.
Svec AL; Strosberg AM
Invest Ophthalmol Vis Sci; 1986 Mar; 27(3):401-5. PubMed ID: 2869005
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical and pharmacological investigation of water/oil microemulsion of non-selective beta blocker for treatment of glaucoma.
Hegde RR; Bhattacharya SS; Verma A; Ghosh A
Curr Eye Res; 2014 Feb; 39(2):155-63. PubMed ID: 24073659
[TBL] [Abstract][Full Text] [Related]
20. Improvement of the ocular bioavailability of timolol by sorbic acid.
Higashiyama M; Inada K; Ohtori A; Tojo K
Int J Pharm; 2004 Mar; 272(1-2):91-8. PubMed ID: 15019072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
